The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025. | As ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...